The Advisory outlines the principles and components of low barrier care, and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

This document updates SAMHSA’s 2018 document and outlines best practices for the implementation and operation of recovery housing. These best practices are intended to serve as a tool for states, governing bodies, providers, recovery house operators, and other interested stakeholders to improve the health of their citizens, reduce incidence of overdose, and promote recovery housing as a key support strategy in achieving and sustaining recovery.

An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.

This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

This guide reviews literature on treating college students’ mental health concerns, such as anxiety, depression, and suicidal thoughts and behaviors; distills the research into recommendations for practice; and provides examples of the ways that these recommendations can be implemented.

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.